TLDR:
- Venture Fund X. L.P. Atlas sold 115,090 shares of Kymera Therapeutics, Inc. stock
- Kymera Therapeutics reported a quarterly revenue increase of 197.5%
Article Summary
Venture Fund X. L.P. Atlas, a major shareholder of Kymera Therapeutics, Inc. (NASDAQ:KYMR), recently sold 115,090 shares of the company’s stock. The transaction took place on March 13th at an average price of $42.23, totaling $4,860,250.70. Following the sale, the insider now holds 4,676,075 shares of Kymera Therapeutics stock, valued at $197,470,647.25. This transaction was disclosed in a filing with the SEC.
Kymera Therapeutics stock opened at $39.51 on the day of the sale. The company has a market capitalization of $2.41 billion, with a PE ratio of -15.68 and a beta of 2.30. Notably, the firm reported a 197.5% increase in quarterly revenue compared to the previous year. Equities research analysts expect Kymera Therapeutics to post -3.21 earnings per share for the current year.
Institutional investors and hedge funds have shown interest in Kymera Therapeutics stock, with Price T Rowe Associates Inc. MD, BVF Inc. IL, Vanguard Group Inc., State Street Corp, and BlackRock Inc. all either increasing or reducing their stakes in the company in recent periods.
Several equity analysts have weighed in on Kymera Therapeutics, with ratings ranging from “peer perform” to “buy”. The average price target for the stock is $39.89. The company focuses on developing small molecule therapeutics that selectively degrade disease-causing proteins, with programs in various clinical trials targeting immunology-inflammation diseases, hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis.
In conclusion, the sale of Kymera Therapeutics shares by Venture Fund X. L.P. Atlas, the significant increase in quarterly revenue, and the interest shown by institutional investors all indicate ongoing market activity and investor confidence in the company’s potential.
